Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 14 bp deletion in exon 3
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-FCGRT, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein FCGRT also known as FCRN or FcRn has a significant role in the immune system by binding to the Fc region of immunoglobulin G (IgG). This binding prolongs the half-life of IgG by preventing its lysosomal degradation. The molecular mass of the FCGRT protein is roughly 52 kDa. It is prominently expressed in epithelial and endothelial cells across several tissues including the placenta and liver ensuring IgG stability in circulation.
Biological function summary
FCGRT/FCRN is involved in the transportation and recycling of IgG antibodies. It forms a complex with beta-2 microglobulin that contributes to its function. This complex allows IgG antibodies to traverse cellular barriers such as epithelial cells without being digested. This protein is important in maintaining humoral immunity by regulating IgG levels in the bloodstream and similar processes can be observed in mouse FCRN and cynomolgus monkey milk indicating a conserved mechanism across species.
Pathways
FCGRT/FCRN plays a part in the neonatal Fc receptor pathway. This pathway influences IgG homeostasis and impacts antigen presentation to T cells. By doing so it affects immune surveillance and immune tolerance mechanisms. The pathway involves interactions with related proteins such as albumin which also binds to FCRN for extending its half-life in serum.
Disruptions in FCGRT/FCRN functionality relate to autoimmune conditions and inflammatory diseases. Conditions such as lupus and myasthenia gravis show altered IgG recycling or transportation implicating FCRN in their pathology. Accordingly researchers have explored FCRN inhibitors as potential therapeutic interventions. These inhibitors aim to modulate the interaction between FCRN and IgG therefore impacting the disease progression linked to these disorders.
